206 related articles for article (PubMed ID: 3141503)
21. Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells.
Nitta T; Yagita H; Azuma T; Sato K; Okumura K
Eur J Immunol; 1989 Aug; 19(8):1437-41. PubMed ID: 2528460
[TBL] [Abstract][Full Text] [Related]
22. Engineering Fab' fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability.
Rodrigues ML; Snedecor B; Chen C; Wong WL; Garg S; Blank GS; Maneval D; Carter P
J Immunol; 1993 Dec; 151(12):6954-61. PubMed ID: 7903100
[TBL] [Abstract][Full Text] [Related]
23. Shock wave permeabilization with ribosome inactivating proteins: a new approach to tumor therapy.
Delius M; Adams G
Cancer Res; 1999 Oct; 59(20):5227-32. PubMed ID: 10537301
[TBL] [Abstract][Full Text] [Related]
24. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
Robert B; Mach JP; Mani JC; Ychou M; Folli S; Artus JC; Pèlegrin A
Cancer Res; 1996 Oct; 56(20):4758-65. PubMed ID: 8840995
[TBL] [Abstract][Full Text] [Related]
25. Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin.
French RR; Hamblin TJ; Bell AJ; Tutt AL; Glennie MJ
Lancet; 1995 Jul; 346(8969):223-4. PubMed ID: 7542357
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.
Blakey DC; Skilleter DN; Price RJ; Watson GJ; Hart LI; Newell DR; Thorpe PE
Cancer Res; 1988 Dec; 48(24 Pt 1):7072-8. PubMed ID: 3263899
[TBL] [Abstract][Full Text] [Related]
27. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
28. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
Gregg EO; Bridges SH; Youle RJ; Longo DL; Houston LL; Glennie MJ; Stevenson FK; Green I
J Immunol; 1987 Jun; 138(12):4502-8. PubMed ID: 3495593
[TBL] [Abstract][Full Text] [Related]
29. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.
Lu J; Guo Z; Pan X; Wang G; Zhang D; Li Y; Tan B; Ouyang L; Yu X
Respir Res; 2006 Mar; 7(1):43. PubMed ID: 16553963
[TBL] [Abstract][Full Text] [Related]
30. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia.
Bolognesi A; Polito L; Farini V; Bortolotti M; Tazzari PL; Ratta M; Ravaioli A; Horenstein AL; Stirpe F; Battelli MG; Malavasi F
J Biol Regul Homeost Agents; 2005; 19(3-4):145-52. PubMed ID: 16602630
[TBL] [Abstract][Full Text] [Related]
31. [Bi-specific F(ab')2 enhances cytolytic activities of LAK cells against human small cell lung cancer (SCLC)].
Azuma A; Niitani H
Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Sep; 29(9):1132-7. PubMed ID: 1661346
[TBL] [Abstract][Full Text] [Related]
32. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F
Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158
[TBL] [Abstract][Full Text] [Related]
33. Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies.
Daha MR; Bloem AC; Ballieux RE
J Immunol; 1984 Mar; 132(3):1197-1201. PubMed ID: 6229578
[TBL] [Abstract][Full Text] [Related]
34. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
Iwahashi T; Okochi E; Ariyoshi K; Watabe H; Amann E; Mori S; Tsuruo T; Ono K
Cancer Res; 1993 Nov; 53(22):5475-82. PubMed ID: 8106147
[TBL] [Abstract][Full Text] [Related]
35. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
37. In vitro bone marrow purging of multidrug-resistant cells with a mouse monoclonal antibody directed against Mr 170,000 glycoprotein and a saporin-conjugated anti-mouse antibody.
Dinota A; Tazzari PL; Michieli M; Visani G; Gobbi M; Bontadini A; Tassi C; Fanin R; Damiani D; Grandi M
Cancer Res; 1990 Jul; 50(14):4291-4. PubMed ID: 1694719
[TBL] [Abstract][Full Text] [Related]
38. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
Tazzari PL; Zhang S; Chen Q; Sforzini S; Bolognesi A; Stirpe F; Xie H; Moretta A; Ferrini S
Br J Cancer; 1993 Jun; 67(6):1248-53. PubMed ID: 8512810
[TBL] [Abstract][Full Text] [Related]
39. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
40. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
